Wednesday, November 13, 2024 11:24:07 AM
YTD 24 $598,887. (9 months) All of 2023, $402,645.
3Q 2023 Revs $258,560. 3Q 2024 Revs $256,752.
3Q 2023 Revs $258,560. 3Q 2024 Revs $256,752.
The revenue performance for Q3 was satisfactory. The company had anticipated a loss in the third quarter due to additional expenses related to ABBIE technology. However, the management and leadership are optimistic about the future and the company’s operations in Q4.$SHMN pic.twitter.com/D3ZTtMcZJD
— SOHM, Inc. (@sohminc) November 13, 2024
The company has published its Q3 report.https://t.co/pw4tJYs2uU $SHMN
— SOHM, Inc. (@sohminc) November 13, 2024
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
